Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy.
Journal
Gastroenterology research and practice
ISSN: 1687-6121
Titre abrégé: Gastroenterol Res Pract
Pays: Egypt
ID NLM: 101475557
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
05
2020
accepted:
15
07
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
18
8
2020
Statut:
epublish
Résumé
We investigated the prognostic significance of pretreatment systemic inflammation response index (SIRI) in locally advanced pancreatic carcinoma (LAPC) patients treated with concurrent chemoradiotherapy (CRT). Present retrospective cohort analysis investigated consecutive 154 LAPC patients who received radical CRT. The SIRI was defined as: SIRI = neutrophil × monocyte/lymphocyte counts. Ideal SIRI cutoff(s) influencing overall survival (OS) and progression-free survival (PFS) results were sought by using receiver operating characteristic (ROC) curve analysis. The primary endpoint was the interaction between the SIRI and OS results. The median follow-up, PFS, and OS durations were 14.3 (range: 2.9-74.6), 7.9 [%95 confidence interval (CI): 5.7-10.1), and 14.7 months (%95 CI: 11.4-18.0) for the entire cohort, respectively. ROC curve analyses determined the ideal SIRI cutoff that exhibiting a significant link with OS and PFS outcomes at the rounded 1.6 point (AUC: 74.3%; sensitivity: 73.8%; specificity: 70.1%).The SIRI <1.6 patients ( Pretreatment SIRI is a novel independent prognosticator that may further enhance the conventional tumor-node-metastases staging system in a more precise prediction of the OS and PFS outcomes of LAPC patients after radical CRT.
Sections du résumé
BACKGROUND
BACKGROUND
We investigated the prognostic significance of pretreatment systemic inflammation response index (SIRI) in locally advanced pancreatic carcinoma (LAPC) patients treated with concurrent chemoradiotherapy (CRT).
METHODS
METHODS
Present retrospective cohort analysis investigated consecutive 154 LAPC patients who received radical CRT. The SIRI was defined as: SIRI = neutrophil × monocyte/lymphocyte counts. Ideal SIRI cutoff(s) influencing overall survival (OS) and progression-free survival (PFS) results were sought by using receiver operating characteristic (ROC) curve analysis. The primary endpoint was the interaction between the SIRI and OS results.
RESULTS
RESULTS
The median follow-up, PFS, and OS durations were 14.3 (range: 2.9-74.6), 7.9 [%95 confidence interval (CI): 5.7-10.1), and 14.7 months (%95 CI: 11.4-18.0) for the entire cohort, respectively. ROC curve analyses determined the ideal SIRI cutoff that exhibiting a significant link with OS and PFS outcomes at the rounded 1.6 point (AUC: 74.3%; sensitivity: 73.8%; specificity: 70.1%).The SIRI <1.6 patients (
CONCLUSION
CONCLUSIONS
Pretreatment SIRI is a novel independent prognosticator that may further enhance the conventional tumor-node-metastases staging system in a more precise prediction of the OS and PFS outcomes of LAPC patients after radical CRT.
Identifiants
pubmed: 32802045
doi: 10.1155/2020/5701949
pmc: PMC7414371
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5701949Informations de copyright
Copyright © 2020 Erkan Topkan et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Oncol. 2009 May 1;27(13):2269-77
pubmed: 19307501
Cytokine. 2008 Sep;43(3):374-9
pubmed: 18701317
Cancer Manag Res. 2019 Jan 18;11:909-919
pubmed: 30697081
Ann Surg. 2019 Jul;270(1):139-146
pubmed: 29334554
World J Gastroenterol. 2015 Sep 14;21(34):9966-73
pubmed: 26379401
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):508-18
pubmed: 22075449
Pancreatology. 2016 Jul-Aug;16(4):599-604
pubmed: 27029854
Anticancer Res. 2019 Apr;39(4):2169-2176
pubmed: 30952764
Best Pract Res Clin Gastroenterol. 2010 Jun;24(3):349-58
pubmed: 20510834
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Cancer. 2016 Jul 15;122(14):2158-67
pubmed: 27152949
Pancreas. 2016 Jan;45(1):21-31
pubmed: 26658038
Br J Cancer. 2013 Mar 19;108(5):997-1003
pubmed: 23385734
Medicine (Baltimore). 2018 Sep;97(36):e12260
pubmed: 30200163
Medicine (Baltimore). 2016 May;95(18):e3582
pubmed: 27149487
J Clin Oncol. 2009 Apr 10;27(11):1806-13
pubmed: 19273710
Cancer J. 2014 May-Jun;20(3):195-202
pubmed: 24855007
Medicine (Baltimore). 2017 Dec;96(50):e9247
pubmed: 29390358
Oncotarget. 2017 May 23;8(21):34954-34960
pubmed: 28430597
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Gastrointest Oncol. 2019 Aug;10(4):703-711
pubmed: 31392051
Anticancer Res. 2017 Feb;37(2):787-793
pubmed: 28179331
Intern Med J. 2014 Jul;44(7):676-82
pubmed: 24750233
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Curr Probl Cancer. 2002 Jul-Aug;26(4):176-275
pubmed: 12399802
J Clin Oncol. 2010 Sep 10;28(26):4045-51
pubmed: 20644090
J Investig Med. 2019 Mar;67(3):691-698
pubmed: 30127099
Nat Rev Cancer. 2013 Nov;13(11):759-71
pubmed: 24154716
Lancet Oncol. 2013 Apr;14(4):317-26
pubmed: 23474363
Lancet Oncol. 2016 Jun;17(6):801-810
pubmed: 27160474
J Exp Clin Cancer Res. 2008 Sep 23;27:41
pubmed: 18808725
Int Immunopharmacol. 2018 Dec;65:503-510
pubmed: 30408627
Cancer Treat Rev. 2013 Aug;39(5):534-40
pubmed: 22995477
Pancreas. 2019 May/Jun;48(5):e45-e47
pubmed: 31090669
JAMA. 2007 Jan 17;297(3):267-77
pubmed: 17227978
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468